OBJECTIVE: The study aimed to determine the baseline prevalence of human papillomavirus (HPV) types in invasive vulvar cancer (IVC) and vulvar intraepithelial neoplasia 3 (VIN 3) cases using data from 7 US cancer registries. MATERIALS AND METHODS: Registries identified eligible cases diagnosed in 1994 to 2005 and requested pathology laboratories to prepare 1 representative block for HPV testing on those selected. Hematoxylin-eosin-stained sections preceding and following those used for extraction were reviewed to confirm representation. Human papillomavirus was detected using L1 consensus polymerase chain reaction (PCR) with PGMY9/11 primers and type-specific hybridization, with retesting of samples with negative and inadequate results with SPF10 primers. For IVC, the confirmatory hematoxylin-eosin slides were re-evaluated to determine histological type. Descriptive analyses were performed to examine distributions of HPV by histology and other factors. RESULTS: Human papillomavirus was detected in 121/176 (68.8%) cases of IVC and 66/68 (97.1%) cases of VIN 3 (p < .0001). Patients with IVC and VIN 3 differed by median age (70 vs 55 y, p = .003). Human papillomavirus 16 was present in 48.6% of IVC cases and 80.9% of VIN 3 cases; other high-risk HPV was present in 19.2% of IVC cases and 13.2% of VIN 3 cases. Prevalence of HPV differed by squamous cell carcinoma histological subtype (p < .0001) as follows: keratinizing, 49.1% (n = 55); nonkeratinizing, 85.7% (n = 14), basaloid, 92.3% (n = 14), warty 78.2% (n = 55), and mixed warty/basaloid, 100% (n = 7). CONCLUSIONS: Nearly all cases of VIN 3 and two thirds of IVC cases were positive for high-risk HPV. Prevalence of HPV ranged from 49.1% to 100% across squamous cell carcinoma histological subtypes. Given the high prevalence of HPV in IVC and VIN 3 cases, prophylactic vaccines have the potential to decrease the incidence of vulvar neoplasia.
OBJECTIVE: The study aimed to determine the baseline prevalence of human papillomavirus (HPV) types in invasive vulvar cancer (IVC) and vulvar intraepithelial neoplasia 3 (VIN 3) cases using data from 7 US cancer registries. MATERIALS AND METHODS: Registries identified eligible cases diagnosed in 1994 to 2005 and requested pathology laboratories to prepare 1 representative block for HPV testing on those selected. Hematoxylin-eosin-stained sections preceding and following those used for extraction were reviewed to confirm representation. Human papillomavirus was detected using L1 consensus polymerase chain reaction (PCR) with PGMY9/11 primers and type-specific hybridization, with retesting of samples with negative and inadequate results with SPF10 primers. For IVC, the confirmatory hematoxylin-eosin slides were re-evaluated to determine histological type. Descriptive analyses were performed to examine distributions of HPV by histology and other factors. RESULTS:Human papillomavirus was detected in 121/176 (68.8%) cases of IVC and 66/68 (97.1%) cases of VIN 3 (p < .0001). Patients with IVC and VIN 3 differed by median age (70 vs 55 y, p = .003). Human papillomavirus 16 was present in 48.6% of IVC cases and 80.9% of VIN 3 cases; other high-risk HPV was present in 19.2% of IVC cases and 13.2% of VIN 3 cases. Prevalence of HPV differed by squamous cell carcinoma histological subtype (p < .0001) as follows: keratinizing, 49.1% (n = 55); nonkeratinizing, 85.7% (n = 14), basaloid, 92.3% (n = 14), warty 78.2% (n = 55), and mixed warty/basaloid, 100% (n = 7). CONCLUSIONS: Nearly all cases of VIN 3 and two thirds of IVC cases were positive for high-risk HPV. Prevalence of HPV ranged from 49.1% to 100% across squamous cell carcinoma histological subtypes. Given the high prevalence of HPV in IVC and VIN 3 cases, prophylactic vaccines have the potential to decrease the incidence of vulvar neoplasia.
Authors: Mario Sideri; Ronald W Jones; Edward J Wilkinson; Mario Preti; Debra S Heller; James Scurry; Hope Haefner; Sallie Neill Journal: J Reprod Med Date: 2005-11 Impact factor: 0.142
Authors: J J Carter; M M Madeleine; K Shera; S M Schwartz; K L Cushing-Haugen; G C Wipf; P Porter; J R Daling; J K McDougall; D A Galloway Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: Mona Saraiya; Meg Watson; Xiaocheng Wu; Jessica B King; Vivien W Chen; Jennifer S Smith; Anna R Giuliano Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Hugo De Vuyst; Gary M Clifford; Maria Claudia Nascimento; Margaret M Madeleine; Silvia Franceschi Journal: Int J Cancer Date: 2009-04-01 Impact factor: 7.396
Authors: Jennifer S Smith; Danielle M Backes; Brooke E Hoots; Robert J Kurman; Jeanne M Pimenta Journal: Obstet Gynecol Date: 2009-04 Impact factor: 7.661
Authors: Kathleen K Thoburn; Robert R German; Mary Lewis; Phyllis Janie Nichols; Faruque Ahmed; Jeannette Jackson-Thompson Journal: Cancer Date: 2007-04-15 Impact factor: 6.860
Authors: L L Villa; R L R Costa; C A Petta; R P Andrade; J Paavonen; O-E Iversen; S-E Olsson; J Høye; M Steinwall; G Riis-Johannessen; A Andersson-Ellstrom; K Elfgren; G von Krogh; M Lehtinen; C Malm; G M Tamms; K Giacoletti; L Lupinacci; R Railkar; F J Taddeo; J Bryan; M T Esser; H L Sings; A J Saah; E Barr Journal: Br J Cancer Date: 2006-11-21 Impact factor: 7.640
Authors: James L Klosky; Brianne Favaro; Kelly R Peck; Jessica L Simmons; Kathryn M Russell; Daniel M Green; Melissa M Hudson Journal: J Cancer Surviv Date: 2015-11-16 Impact factor: 4.442
Authors: Brenda Y Hernandez; Charles F Lynch; Owen T M Chan; Marc T Goodman; Elizabeth R Unger; Martin Steinau; Trevor D Thompson; Maura Gillison; Christopher Lyu; Mona Saraiya Journal: Oral Oncol Date: 2019-03-05 Impact factor: 5.337
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: David A Siegel; Reda Wilson; Edward J Wilkinson; Julia W Gargano; Meg Watson; Brenda Y Hernandez; Marc T Goodman; Charles F Lynch; Elizabeth R Unger; Mona Saraiya Journal: Arch Pathol Lab Med Date: 2016-10-20 Impact factor: 5.534
Authors: Van K Morris; Asif Rashid; Miguel Rodriguez-Bigas; Prajnan Das; George Chang; Aki Ohinata; Jane Rogers; Christopher Crane; Robert A Wolff; Cathy Eng Journal: Oncologist Date: 2015-09-17
Authors: Aditi Sagdeo; Rachel H Gormley; Katrina Abuabara; Stephen K Tyring; Peter Rady; David E Elder; Carrie L Kovarik Journal: J Am Acad Dermatol Date: 2014-03 Impact factor: 11.527
Authors: Elaine W Flagg; S Deblina Datta; Mona Saraiya; Elizabeth R Unger; Edward Peters; Lauren Cole; Vivien W Chen; Thomas Tucker; Mary Jane Byrne; Glenn Copeland; Won Silva; Meg Watson; Hillard Weinstock Journal: Cancer Causes Control Date: 2014-02-28 Impact factor: 2.506
Authors: Marc T Goodman; Mona Saraiya; Trevor D Thompson; Martin Steinau; Brenda Y Hernandez; Charles F Lynch; Christopher W Lyu; Edward J Wilkinson; Thomas Tucker; Glenn Copeland; Edward S Peters; Sean Altekruse; Elizabeth R Unger Journal: Eur J Cancer Date: 2015-11-18 Impact factor: 9.162